Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 57Recurrence 7Neoplasms, Plasma Cell 5Neoplasms 4Smoldering Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Immunoglobulin Light-chain Amyloidosis 1Glioblastoma 1Disease 1Chromosome 17 deletion 1

Interventions

Etoposide 5Cyclophosphamide 5Vincristine 4Methotrexate 4Doxorubicin 4Cytarabine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Leucovorin 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3Calcium Dobesilate 3venetoclax 2prednylidene 2exifone 2deltacortene 2calaspargase pegol 2azathiopurine 2Whole-Body Irradiation 2Thioguanine 2Tacrolimus 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × daratumumab × Clear all
NCT06253637 2026-03-05

DARATALL-VHR

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Active not recruiting
31 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡